Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative evaluation of healthcare information provided to patients with thoracic malignancies: patient satisfaction survey of the Japan Lung Cancer Society.

International journal of clinical oncology·2026
Same author

Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLC.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Interstitial Lung Disease in Patients With Unresectable Stage III NSCLC Treated With Chemoradiotherapy Followed by Durvalumab in Japan: Analysis From the Multicenter Prospective AYAME Study.

Thoracic cancer·2026
Same author

Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan.

Cancer science·2026
Same author

Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2.

Cancer science·2026
Same author

Potential Immune Microenvironment Biomarkers in SCLC: J-TAIL-2 Observational Study.

JTO clinical and research reports·2026

Related Experiment Video

Updated: Jul 3, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

[Pemetrexed].

Junko Sudoh1, Akihiko Gemma

  • 1Dept. of Respiratory Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 18, 2008
PubMed
Summary

Pemetrexed is an effective antifolate chemotherapy for mesothelioma and non-small cell lung cancer (NSCLC). Vitamin supplementation with pemetrexed reduces toxicity, making it a valuable option for high-risk patients.

Area of Science:

  • Oncology
  • Pharmacology

Context:

  • Pemetrexed is a multi-targeted antifolate chemotherapy agent.
  • It is approved for mesothelioma and second-line advanced non-small cell lung cancer (NSCLC).

Purpose:

  • To evaluate the efficacy and safety of pemetrexed in cancer treatment.
  • To assess pemetrexed's role in mesothelioma and NSCLC, including combination therapy and second-line treatment.

Summary:

  • Pemetrexed demonstrated superior survival and response rates when combined with cisplatin for mesothelioma.
  • In NSCLC, pemetrexed showed comparable efficacy to docetaxel with a better safety profile, particularly reduced neutropenia.
  • Vitamin supplementation (folic acid and vitamin B12) significantly mitigated pemetrexed's hematologic and gastrointestinal toxicities.

More Related Videos

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: Jul 3, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Impact:

  • Pemetrexed is a standard treatment option for second-line NSCLC and mesothelioma.
  • Vitamin supplementation enhances pemetrexed's tolerability, especially in elderly or frail patients.
  • Pemetrexed offers a favorable risk-benefit profile, particularly in vulnerable patient populations.